Athens Research/Cambio - Excellence in Molecular Biology/0.25g/10-1050-02

价格
面议
货号:10-1050-02
浏览量:42
品牌:Athens Research
服务
全国联保
正品保证
正规发票
签订合同
商品描述
Oligo Synthesis

Oligo Synthesis : CEPs

Prices quoted are for single packs only. For multiples of the same product please request a quote. Some of Glen"sproductsarehazardousandmay be subject to additional shipping charges. Full product information is available onGlen Research"s website.

  • Catalogue
  • Description
  • Protocols
  • Notes
  • Applications & Benefits

dU-CE Phosphoramidite

dU-CE Phosphoramidite

Glen Research

Catalogue No.DescriptionPack SizePriceQty
  • Change to:
  • €
10-1050-02dU-CE Phosphoramidite0.25g£80.00£76.00Offer until : 31-Mar-2021Offer Code : GLEN55% off all Glen productsView OfferQuantityAdd to Order
10-1050-90dU-CE Phosphoramidite100µmoles£50.00£47.50Offer until : 31-Mar-2021Offer Code : GLEN55% off all Glen productsView OfferQuantityAdd to Order

dU-CE Phosphoramidite

dU-CE Phosphoramidite

Glen Research

Structure

Catalog Number: 10-1050-xx

Description: dU-CE Phosphoramidite

5"-Dimethoxytrityl-2"-deoxyUridine,3"-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite
Formula: C39H47N4O8PM.W.: 730.8F.W.: 290.17

Diluent: Anhydrous Acetonitrile
Coupling: No changes needed from standard method recommended by synthesizer manufacturer.
Deprotection: No changes needed from standard method recommended by synthesizer manufacturer.
Storage: Refrigerated storage, maximum of 2-8°C, dry
Stability in Solution: Similar to dA,C,G,T-CE Phosphoramidites

DUPLEX EFFECTS

The design of primers is frequently complicated by the degeneracy of the genetic code. Three strategies are now available to confront this problem. In the first, a mixed base addition (N) is used to form the degenerate site. This approach is best if the number of degenerate sites is small. A second option is the use of 2’-deoxyInosine or 2’-deoxyNebularine which exhibit low, but unequal, hydrogen bonding to the other four bases. The third option is the use of a universal nucleoside. In this strategy, the base analog does not hybridize significantly to the other four bases and makes up some of the duplex destabilization by acting as an intercalating agent. 3-Nitropyrrole 2’-deoxynucleoside (M) is the first example of a set of universal bases. Subsequently, 5-nitroindole was determined to be an effective universal base and to be superior to 3-nitropyrrole, based on duplex melting experiments.

The modified bases designated P and K show considerable promise as degenerate bases. The pyrimidine derivative P, when introduced into oligonucleotides, base pairs with either A or G, while the purine derivative K base pairs with either C or T. A dP dK mix also can serve as a mixed base with much less degeneracy than dA dC dG dT (N).

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

dU-CE Phosphoramidite

dU-CE Phosphoramidite

Glen Research

Material Safety Data Sheet

???Glen Report 23.1: DNA Methylation Revisited

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

dU-CE Phosphoramidite

dU-CE Phosphoramidite

Glen Research

dU-CE Phosphoramidite

5"-Dimethoxytrityl-2"-deoxyUridine,3"-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite
Formula: C39H47N4O8PM.W.: 730.8F.W.: 290.17

Diluent: Anhydrous Acetonitrile
Coupling: No changes needed from standard method recommended by synthesizer manufacturer.
Deprotection: No changes needed from standard method recommended by synthesizer manufacturer.
Storage: Refrigerated storage, maximum of 2-8°C, dry
Stability in Solution: Similar to dA,C,G,T-CE Phosphoramidites
Material Safety Data Sheet

EXTINCTION DATA

ItemNucleosideλMax-1Emax-1λMax-2Emax-2E260
(nm)(ml/µmole)nm(ml/µmole)(ml/µmole)
10-1050dU2621010

DILUTION/COUPLING DATA

The table below shows pack size data and, for solutions, dilutions and approximate couplings based on normal priming procedures. Please link for more detailed usage information with the various synthesizers.

ABI 392/394
Cat.No.PackSizeGrams/Pack0.1M Dil.(mL)LV40LV20040nm0.2µm1µm10µm
Approximate Number of Additions
10-1050-020.25grams.25grams3.42100.6760.437.7527.4520.135.03
10-1050-90100µmoles.073grams120127.55.4541
Expedite
Cat.No.PackSizeGrams/PackDilution(mL)Molarity50nm0.2µm1µm15µm
Approximate Number of Additions
10-1050-020.25grams.25grams5.11.06795.859.8843.555.99
10-1050-90100µmoles.073grams1.5.06723.614.7510.731.48
Beckman
Cat.No.PackSizeGrams/PackDilution(mL)Molarity30nm200nm1000nm
Approximate Number of Additions
10-1050-020.25grams.25grams5.11.06797.460.8844.27
10-1050-90100µmoles.073grams1.5.06725.215.7511.45

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

dU-CE Phosphoramidite

dU-CE Phosphoramidite

Glen Research

The design of primers is frequently complicated by the degeneracy of the genetic code. Three strategies are now available to confront this problem.

  1. A mixed base addition (N) is used to form the degenerate site. This approach is best if the number of degenerate sites is small.
  2. The use of 2"-deoxyInosine or 2"-deoxyNebularine which exhibit low, but unequal, hydrogen bonding to the other 4 bases.
  3. The use of a universal nucleotide. In this strategy, the base analog does not hybridise significantly to the other 4 bases and makes up some of the duplex destabilisation by acting as an intercalating agent.

EXTINCTION DATA

ItemNucleosideλMax-1Emax-1λMax-2Emax-2E260
(nm)(ml/µmole)nm(ml/µmole)(ml/µmole)
10-1050dU2621010

DILUTION/COUPLING DATA

The table below shows pack size data and, for solutions, dilutions and approximate couplings based on normal priming procedures. Please link formore detailed usage informationwith the various synthesizers.

ABI 392/394
Cat.No.PackSizeGrams/Pack0.1M Dil.(mL)LV40LV20040nm0.2µm1µm10µm
Approximate Number of Additions
10-1050-020.25grams.25grams3.42100.6760.437.7527.4520.135.03
10-1050-90100µmoles.073grams120127.55.4541
Expedite
Cat.No.PackSizeGrams/PackDilution(mL)Molarity50nm0.2µm1µm15µm
Approximate Number of Additions
10-1050-020.25grams.25grams5.11.0795.859.8843.555.99
10-1050-90100µmoles.073grams1.5.0723.614.7510.731.48
Beckman
Cat.No.PackSizeGrams/PackDilution(mL)Molarity30nm200nm1000nm
Approximate Number of Additions
10-1050-020.25grams.25grams5.11.0797.460.8844.27
10-1050-90100µmoles.073grams1.5.0725.215.7511.45

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

Myeloperoxidase Enzyme Immunoassay Kit 髓过氧化物酶 免疫分析试剂盒 Human MPO EIA KIT FEATURES: USE - Measure human MPO in a variety of matrices SAMPLE -Serum, Platelet-Poor Heparin Plasma, Saliva, Urine or Tissue Culture Media SAMPLES / KIT - 40 in duplicate SENSITIVITY - 0.068 ng/mL STABILITY - liquid reagents stable at 4°C QUICK RESULTS - 2.5 HOURS Myeloperoxidase (MPO) is a tetrameric heme-containing protein abundantly produced in neutrophil granulocytes where it plays an important anti-microbial role. During degranulation MPO is released into the extracellular space. There, as part of the neutrophils “respiratory burst”, it produces hypochlorous acid from hydrogen peroxide and Cl–. MPO also uses hydrogen peroxide to oxidize tyrosine to the tyrosyl radical. Both hypochlorous acid and tyrosyl are cytotoxic and when present can kill bacteria and other pathogens. Hereditary deficiency of myeloperoxidase predisposes individuals to immune deficiency. Studies have shown an association between elevated MPO levels and coronary artery disease, and in 2003 it was suggested that MPO may serve as a sensitive predictor of myocardial infarction in patients complaining of chest pain. Since that time the clinical utility of MPO testing in cardiac patients has been solidly established in the literature with well over 100 papers published. In 2010 this clinical application was further refined by additional studies which determined that measuring both MPO and C-reactive protein (CRP) provided more accurate prediction of mortality risk than measuring just CRP alone.